Biogen will present new findings at the Alzheimer’s Association International Conference (AAIC) 2026, set for July 12–15 in London. This includes data from the Phase 2 CELIA study of diranersen, an investigational tau-targeting ASO, as well as additional analyses of LEQEMBI (lecanemab).
Subscribe
Biotechnology
Chronic Illness Management
Therapy Options
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
Key Takeaways:
- Biogen will share new Alzheimer’s data at AAIC 2026.
- The conference runs from July 12–15 in London, UK.
- Presentations feature the Phase 2 CELIA study on diranersen.
- Diranersen targets tau protein via antisense oligonucleotide technology.
- New analyses of LEQEMBI (lecanemab) will also be presented.
The Importance of AAIC 2026
The Alzheimer’s Association International Conference (AAIC) serves as one of the most influential global forums for sharing the latest research on Alzheimer’s disease and related dementias. From July 12 to 15, 2026, leading scientists and medical professionals will convene in London to discuss groundbreaking developments in diagnosis, treatment, and patient care.
Biogen’s Expanding Alzheimer’s Focus
Biogen Inc., headquartered in Cambridge, Massachusetts, announced its participation in the upcoming conference. According to the company, this event will be an opportunity to present cutting-edge data from across its portfolio, reflecting its continued dedication to innovative treatments for people affected by Alzheimer’s.
Spotlight on Diranersen
One of the most significant presentations will highlight findings from the Phase 2 CELIA study on diranersen. As an investigational antisense oligonucleotide (ASO) designed to target tau proteins, diranersen aims to address the hallmark pathological features of Alzheimer’s disease. While in-depth results remain under wraps, the conference offers an important venue for unveiling the latest research on this therapy.
New Analyses on LEQEMBI (Lecanemab)
Biogen’s presentations at AAIC 2026 will also include new analyses related to LEQEMBI (lecanemab). This therapy has generated attention for its potential role in altering the progression of Alzheimer’s disease. The additional data to be shared may give further insight into its clinical profile and possible future applications.
The Road Ahead
With the Alzheimer’s Association International Conference drawing near, the medical community awaits Biogen’s upcoming results. These data highlight the company’s broader commitment to tackling one of the most pressing challenges in neurology. As experts gather in London, the focus remains on advancing therapies that can improve lives and deepen understanding of the disease’s complex mechanisms.
